Form 4: Phyllis Yale Increases BMY Equity Stake via DSU Grant
Director Equity Compensation
Director Phyllis R. Yale acquired 577.082 deferred share units in Bristol-Myers Squibb as part of director compensation.
Summary
- Director Phyllis R. Yale was granted 577.082 Deferred Share Units (DSUs) on March 31, 2026.
- The units were acquired at a price of $60.65 per share.
- Following this transaction, the director holds a total of 43,903.777 shares in the company.
- These units are settleable in common stock upon the director's departure from the board or at a previously specified future date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Demonstrates continued alignment of director interests with shareholders through equity-based compensation.
- Reflects ongoing participation in the company's deferred compensation plan for non-employee directors.
Negatives
- None identified; this is a routine compensatory transaction.
Risks
- Value of deferred share units is subject to fluctuations in the underlying common stock price of Bristol-Myers Squibb.
Future Outlook
The filing does not provide forward-looking guidance regarding company operations or financial performance.
Industry Context
StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the pharmaceutical industry, intended to ensure long-term alignment between leadership and shareholder value.
Comparison to Industry Standards
- The use of Deferred Share Units (DSUs) for non-employee directors is a common practice among large-cap pharmaceutical companies like Pfizer, Merck, and Eli Lilly to defer compensation and maintain equity exposure.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation | Grant of deferred share units under the 1987 Deferred Compensation Plan for Non-Employee Directors. | 03/31/2026 | Standard maintenance of director equity holdings. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensatory grant.
Next Steps
- The director will continue to hold these units until retirement from the board or the specified settlement date.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of the transaction involving the acquisition of deferred share units. |
| 04/02/2026 | Date the Form 4 was signed and filed with the SEC. |
Keywords
Bristol-Myers Squibb, BMY, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.